Cover Image
市場調查報告書

全球抗病毒藥物市場預測:市場規模、區分、市場佔有率、競爭情形

Global Anti-Viral drugs Market Outlook - Market size, Segmentation, Market Share and Competitive Landscape (2016-2021)

出版商 Mordor Intelligence LLP 商品編碼 367215
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
全球抗病毒藥物市場預測:市場規模、區分、市場佔有率、競爭情形 Global Anti-Viral drugs Market Outlook - Market size, Segmentation, Market Share and Competitive Landscape (2016-2021)
出版日期: 2016年01月01日 內容資訊: 英文
簡介

本報告提供全球抗病毒藥物市場相關調查分析、市場概要、市場動態、各市場區隔分析、競爭情形等系統性資訊。

簡介

調查手法

摘要整理

主要的推論

市場概要與產業趨勢

  • 目前市場方案
  • 市場概要
  • 新的發展
  • 五力

推動因素、阻礙因素、機會、課題分析 (DROC)

  • 推動市場要素
  • 阻礙市場要素
  • 主要課題
  • 目前機會

全球抗病毒藥物市場:各標的疾病

  • HIV/AIDS
  • 肝炎
  • 皰疹
  • 流感

全球抗病毒藥物市場:抗病毒的各類型

  • IPR保護
  • 學名藥

全球抗病毒藥物市場:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 中東、非洲
  • 南美

競爭情形

  • M&A分析
  • 新產品銷售
  • 契約、聯盟、夥伴關係

主要供應商分析

  • Abbott
  • Bristol-Myers-Squibb
  • Gilead
  • GlaxoSmithKline
  • Johnson & Johnson
  • MedImmune/AstraZeneca
  • Merck & Co
  • Roche
  • Schering-Plough

投資機會預測

市場未來發展預測

目錄

In the year 2015, the Global Anti-Viral drugs market was valued at USD XX Million. It is expected to increase to an estimated market value of USD XX Million while growing at a CAGR of XX.X% during the forecast period. Anti-Viral drugs are the drugs used to treat viral infections which can range from infections like flu to AIDS (Acquired Immuno Deficiency Syndrome). Just like common cold which is also caused by virus, most viral diseases are extremely difficult to cure and what the anti-viral drugs mostly do is slow down the reproduction of virus which in some cases enables immune system to eliminate the virus (as in case of flu) while slowing down the disease progression in other cases (as in case of AIDS).

The need of anti-viral drugs for patient's lifetime in case of diseases like HIV/AIDS along with well-established supply chain that facilitates easy procurement are driving the growth of this market. While the increasing use of generics along with lack of incentivization and lack of curative anti-viral drugs for indications like HIV/AIDS are hindering the growth of this market.

This market has been segmented on the basis of target disease into HIV/AIDS, Hepatitis, Herpes and Influenza. The market has also been segmented by type of anti-viral into IPR Protected and Generic.

Based on geography, this market has been segmented into North America (United States, Canada and Mexico), Europe (United Kingdom, Germany, France, Italy, Spain and Rest of Europe), Asia-Pacific (APAC) (China, Japan, India, Australia, South Korea and Rest of APAC), Middle-East and Africa (MEA) (GCC, South Africa and Rest of MEA), South America (Brazil, Argentina and Rest of South America).

Lack of broad spectrum anti-viral drugs is currently the huge unmet need in this market and presents a great opportunity to companies. While the negative impact of viral vaccines on the growth of anti-viral drugs market and increasing focus on prevention rather than cure of viral diseases are currently the challenges faced by this market.

There are several major players operating in this market and some of them include: Abbott, Bristol-Myers-Squibb, Gilead, GlaxoSmithKline, Johnson & Johnson, MedImmune/AstraZeneca, Merck & Co, Roche and Schering-Plough.

Key Deliverables in the Study:

  • 1. Market analysis for the Global Anti-Viral Drugs Market, with region specific assessments and competition analysis on global and regional scales
  • 2. Market definition along with the identification of key drivers and restraints
  • 3. Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale
  • 4. Extensively researched competitive landscape section with profiles of major companies along with their market shares
  • 5. Identification and analysis of the macro and micro factors that affect the Global Anti-Viral Drugs market on both global and regional scales
  • 6. A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information
  • 7. A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market
  • 8. Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped

XX Commercial in Confidence.

Table of Contents

  • Introduction
    • Study deliverables
    • Market Definition
    • Sizing Units
    • Base Currency
    • Review and Forecast period
    • General Study Assumptions
  • Research Methodology
    • Introduction
    • Analysis Methodology
    • Econometric Forecast
    • Expert validation
    • Study Timeline
  • Executive Summary
  • Key Inferences
  • Market Overview and Industry Trends
    • Current Market Senario
    • Market Overview
    • New Developments
    • Porter's Five Forces
      • Bargaining Power of Suppliers
      • Bargaining Power of Consumers
      • Threat to new entrants
      • Threat to substitute products and services
      • Competitive Rivalry within the industry
  • Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
    • Market Drivers
      • Anti virals needed for patient's lifetime in case of diseases like HIV/AIDS
      • Well established supply chain facilitates easy procurement
    • Market Restraints
      • Increasing use of generics
      • Lack of incentivization
      • Lack of curative anti virals for indications like HIV/AIDS
    • Key Challenges
      • Market negatively impacted by growth of viral vaccines market
      • Increasing focus on prevention rather than cure of viral diseases
    • Current Opportunities in the Market
      • Lack of broad spectrum anti viral drugs
  • Global Antivirals Drugs Market, by Target Disease
    • HIV/AIDS
    • Hepatitis
    • Herpes
    • Influenza
  • Global Antivirals Drugs Market, by Type of Anti-Viral
    • IPR Protected
    • Generics
  • Global Antiviral Drugs Market, By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • United Kingdom
      • Germany
      • France
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific (APAC)
      • Japan
      • China
      • India
      • South Korea
      • Australia
      • Rest of APAC
    • Middle East & Africa (MEA)
      • GCC Countries
      • South Africa
      • Rest of MEA
    • South America
      • Brazil
      • Argentina
      • Rest of South America
  • Competitive Landscape
    • Merger and acquisition analysis
    • New Product Launches
    • Agreements, Collaborations and Parterships
  • Key Vendor Analysis
    • Abbott
    • Bristol-Myers-Squibb
    • Gilead
    • GlaxoSmithKline
    • Johnson & Johnson
    • MedImmune/AstraZeneca
    • Merck & Co
    • Roche
    • Schering-Plough
  • Analyst Outlook for Investment Opportunities
  • Future Outlook of the Market
Back to Top